Cellectar Biosciences (CLRB) Biotech Showcase 2026 summary

Key clinical results and regulatory progress

• Achieved breakthrough and PRIME designations for lead asset CLR 131 based on strong phase II-B data in Waldenstrom's macroglobulinemia, with a major response rate of 58.2% and overall response rate of 84%.

• Conditional marketing authorization submission to EMA planned for early Q3 2026, with anticipated approval and commercialization in the first half of 2027.

• U.S. FDA accelerated application in preparation, with potential approval within 6–8 months of study initiation; estimated $15M cost to approval.

• High likelihood of regulatory success, with 79–80% approval rates for breakthrough/CMA pathways.

• Clean safety profile with manageable cytopenias and negligible off-target effects in clinical studies.

Pipeline and development strategy

• Initiated phase I-B study of CLR 125 (Auger emitter) in triple-negative breast cancer in Q1, with imaging and initial response data expected in the first half of the year.

• CLR 225 for pancreatic cancer is phase I ready, with timing for initiation to be determined.

• Platform enables pan-tumor targeting and selection of optimal isotopes for each cancer type, validated in multiple solid and liquid tumor models.

• Early pipeline includes alpha and beta emitters, with investment decisions based on strategic prioritization.

• Pediatric high-grade glioma and aggressive B-cell malignancies show promising activity and extended progression-free survival.

Market opportunity and commercialization plans

• U.S. Waldenstrom's macroglobulinemia market includes 11,500 second-line patients, with 1,000 lacking available treatments; 60% of treatments are off-label.

• EU market is 30% larger than U.S., with additional opportunities via regulatory reciprocity.

• Commercialization strategy focuses on partnerships, especially prior to U.S. phase III confirmatory study initiation.

• Minimal marketing investment required due to concentrated patient population and integrated care networks.

• Financial position as of October: ~$18M cash, 4M+ shares outstanding, fully diluted at 7.5M.